Literature DB >> 12034258

Rituximab in the treatment of pediatric small bowel transplant patients with posttransplant lymphoproliferative disorder unresponsive to standard treatment.

W McGhee1, G V Mazariegos, R Sindhi, K Abu-Elmagd, J Reyes.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12034258     DOI： 10.1016/s0041-1345(02)02714-8

Source DB:  PubMed          Journal:  Transplant Proc        ISSN： 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  2 in total

1.  2003 report of the intestine transplant registry: a new era has dawned.

Authors:  David Grant; Kareem Abu-Elmagd; Jorge Reyes; Andreas Tzakis; Alan Langnas; Thomas Fishbein; Olivier Goulet; Douglas Farmer
Journal:  Ann Surg       Date:  2005-04       Impact factor: 12.969

2.  Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndrome.

Authors:  Kandai Nozu; Kazumoto Iijima; Masato Fujisawa; Atsuko Nakagawa; Norishige Yoshikawa; Masafumi Matsuo
Journal:  Pediatr Nephrol       Date:  2005-08-16       Impact factor: 3.714
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.